Morgan Stanley maintains a "overweight" rating on GUSHENGTANG(02273) with a target price of 62 Hong Kong dollars.
Currently, private hospitals are not required to participate in volume-based procurement. The company expects the group to achieve a revenue growth of over 20% this year, with a profit increase of over 25%.
Morgan Stanley released a research report stating that they are maintaining a "buy" rating for GUSHENGTANG (02273) with a target price of 62 Hong Kong dollars. Currently, private hospitals are not required to participate in volume-based procurement. The bank expects the group to achieve revenue growth of over 20% this year, with profit growth expected to be over 25%.
Related Articles
STERLING GP(01825): Wu Jing appointed as independent non-executive director.
Pacific Legend (08547): General authorization for the issuance of new shares has expired.
MGM China (02282) bought back 1.2 million shares for HK$18.758 million on September 18th.
STERLING GP(01825): Wu Jing appointed as independent non-executive director.
Pacific Legend (08547): General authorization for the issuance of new shares has expired.
MGM China (02282) bought back 1.2 million shares for HK$18.758 million on September 18th.
